Long-Term Data from the ABCSG-12 Trial of Adjuvant Zoledronic Acid and Endocrine Therapy
OVERVIEW OF ACTIVITY
The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

LEARNING OBJECTIVE
- Recall the long-term effects on survival and the associated safety of adding zoledronic acid to anastrozole/goserelin or tamoxifen/goserelin for premenopausal patients with early-stage breast cancer.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

- Harold J Burstein, MD, PhD
  Associate Professor of Medicine
  Harvard Medical School
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts

No real or apparent conflicts of interest to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests:

- Abraxis BioScience Inc
- Allos Therapeutics
- Amgen Inc
- AstraZeneca Pharmaceuticals LP
- Aureon Laboratories Inc
- Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc
- Biogen Idec
- Boehringer Ingelheim Pharmaceuticals Inc
- Bristol-Myers Squibb Company
- Celgene Corporation
- Cephalon Inc
- Daiichi Sankyo Inc
- Dendreon Corporation
- Eisai Inc
- EMD Serono Inc
- Genentech BioOncology
- Genomic Health Inc
- Novartis Pharmaceuticals Corporation
- OSI Oncology
- Sanofi-Aventis
- Seattle Genetics

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Last review date: January 2011
Expiration date: January 2012
To go directly to slides and commentary, click here.

On June 1, 2008, Martine Piccart-Gebhart served as the discussant for Mike Gnant’s historic ASCO plenary presentation of the Austrian ABCSG-12 study documenting a disease-free survival advantage with adjuvant zoledronate (ZDA) in premenopausal women with ER-positive breast cancer. Martine’s eloquent review of the topic and her explanation of the so-called “seed and soil” hypothesis made these findings even more provocative. Yet when it came down to the bottom line, she urged the audience to hold off on using bisphosphonates outside a protocol setting and to wait a few more months until another major trial, the AZURE study, was reported. Like many recent adjuvant trials, AZURE had fewer events than anticipated, and it was not until the recent San Antonio meeting, more than two years later, that Rob Coleman presented the data in an unplanned early analysis.

Overall, the study struck out cold (hazard ratio of 0.98 for its primary endpoint, disease-free survival), making Martine’s cautious approach truly prescient. However, from the podium Dr Coleman suggested that there might be more to this story — specifically, a planned subset analysis demonstrated that the postmenopausal women in the trial (only about a third) had fewer recurrences on bisphosphonates (odds ratio of 0.76). This seems somewhat in line with the Austrian study, which was restricted to premenopausal women with suppressed ovarian function and raises the possibility that low estrogen levels in the bone microenvironment may be contributing to the benefit of ZDA. There were several other important but difficult-to-decipher aspects of these studies, including that very few of the patients on the Austrian trial received chemo, whereas more than 90 percent of those in AZURE did, and the incidence of ONJ was quite different (zero cases in the Austrian study and 17 in AZURE).

To further complicate the issue, an update of the Austrian study was also reported at this year’s meeting and demonstrated continued improvement in DFS and OS with more follow-up (median 62 months). Similarly, the ZO-FAST trial — part of a trio of studies evaluating ZDA in postmenopausal women on adjuvant letrozole — was also presented in San Antonio and continued to demonstrate better bone density and slightly fewer recurrences.
Two major US cooperative group trials investigating this question have yet to report — NSABP-B-34, evaluating the oral agent clodronate, and SWOG-S0307, comparing zoledronate to clodronate to ibandronate. Although on the SWOG study all patients receive a bisphosphonate, it is worth remembering that a recently reported MRC study in multiple myeloma reported greater survival with up-front ZDA than with clodronate.

Up until now, no one has known what to do clinically about this confusing situation, and our Patterns of Care studies have demonstrated that approximately a quarter of oncologists have been offering adjuvant bisphosphonates to premenopausal patients off study since the data were initially presented at ASCO 2008. This has likely come to a grinding halt, closing that chapter for now with a resounding thud. But is this really the end of adjuvant bisphosphonates? Or down the road some time, might we learn that this interesting story has a very different ending?

Next up in this series, select San Antonio papers on a suddenly exciting part of the field — triple-negative breast cancer.

Neil Love, MD
Research To Practice
Miami, Florida
Long-Term Data from the ABCSG-12 Trial of Adjuvant Zoledronic Acid and Endocrine Therapy

Presentation discussed in this issue

Gnant M et al. The carry-over effect of adjuvant zoledronic acid: Comparison of 48- and 62-month analyses of ABCSG-12 suggests that the benefits of combining zoledronic acid with adjuvant endocrine therapy persist long after completion of therapy. San Antonio Breast Cancer Symposium 2010; Abstract P5-11-02.

Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)
Endpoints

- Primary: Disease-free survival (local recurrence, contralateral breast cancer [BC], distant metastasis, secondary carcinoma, death)
  - Secondary:
    - Relapse-free survival (local recurrence, contralateral BC, distant metastasis, secondary carcinoma)
    - Overall survival (OS)
    - Safety
    - Bone mineral density (substudy)


Eligibility

- Premenopausal status
- Prior surgery for Stage I or II ER+ or PR+ breast cancer
- <10 positive lymph nodes
- Scheduled to receive standard therapy with goserelin for 3 yrs
- No T1a (except yT1a), T4d or yT4 breast cancer
- No history of other neoplasms
- No preoperative radiotherapy

**Study Schema**

Eligibility (N = 1,803)
- Primary surgery
- Treatment with goserelin x 3 yrs

- TAM\(^1\) x 3 yrs
- TAM\(^1\) + ZOL\(^2\) x 3 yrs
- ANA\(^3\) x 3 yrs
- ANA\(^3\) + ZOL\(^2\) x 3 yrs

1 Tamoxifen 20 mg/day
2 Zoledronic acid (ZOL) 4 mg q 6 mos
3 Anastrozole (ANA) 1 mg/day

Gnant M et al. *Proc SABCS* 2010;Abstract P5-11-02.

---

**Efficacy Results: ZOL versus Endocrine Therapy Alone**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>ZOL</th>
<th>No ZOL</th>
<th>HR (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-free survival</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48 mos (n = 899; 904)</td>
<td>94%</td>
<td>91%</td>
<td>0.64 (p = 0.01)</td>
</tr>
<tr>
<td>62 mos (n = 900; 903)</td>
<td>92%</td>
<td>88%</td>
<td>0.68 (p = 0.008)</td>
</tr>
<tr>
<td>Overall survival</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48 mos (n = 899; 904)</td>
<td>98%</td>
<td>97%</td>
<td>0.60 (p = 0.10)</td>
</tr>
<tr>
<td>62 mos (n = 900; 903)</td>
<td>97%</td>
<td>95%</td>
<td>0.67 (p = 0.143)</td>
</tr>
</tbody>
</table>

Gnant M et al. *Proc SABCS* 2010;Abstract P5-11-02.
## Efficacy Results: ZOL versus Endocrine Therapy Alone in TAM and ANA Groups

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>ZOL</th>
<th>No ZOL</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-free survival</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAM (n = 450; 450)</td>
<td>92%</td>
<td>88%</td>
<td>0.67 (0.44, 1.03)</td>
</tr>
<tr>
<td>ANA (n = 450; 453)</td>
<td>91%</td>
<td>87%</td>
<td>0.68 (0.45, 1.02)</td>
</tr>
</tbody>
</table>

Gnant M et al. *Proc SABCS* 2010; Abstract P5-11-02.

## Adverse Events

<table>
<thead>
<tr>
<th>Event</th>
<th>TAM alone (n = 450)</th>
<th>TAM + ZOL (n = 450)</th>
<th>ANA alone (n = 453)</th>
<th>ANA + ZOL (n = 450)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthralgia</td>
<td>7.8%</td>
<td>9.3%</td>
<td>19.0%</td>
<td>22.9%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Bone pain</td>
<td>22.7%</td>
<td>32.7%</td>
<td>33.1%</td>
<td>44.9%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>2.0%</td>
<td>8.2%</td>
<td>2.6%</td>
<td>10.7%</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

* p-values are for a four-group comparison.

Gnant M et al. *Proc SABCS* 2010; Abstract P5-11-02.
### Serious Adverse Events

<table>
<thead>
<tr>
<th></th>
<th>T alone (n = 450)</th>
<th>TAM + ZOL (n = 450)</th>
<th>ANA alone (n = 453)</th>
<th>ANA + ZOL (n = 450)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fracture</td>
<td>1.8%</td>
<td>0.9%</td>
<td>1.5%</td>
<td>1.3%</td>
<td>0.73</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>0.2%</td>
<td>1.1%</td>
<td>0</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>Uterine polyps</td>
<td>6.4%</td>
<td>7.8%</td>
<td>0.2%</td>
<td>0.7%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>6.0%</td>
<td>7.3%</td>
<td>2.0%</td>
<td>0.7%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Osteonecrosis of the jaw</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>−</td>
</tr>
</tbody>
</table>

* p-values are for a four-group comparison.


### Conclusions

- The addition of ZOL to endocrine therapy for 3 years was associated with a durable benefit in disease-free survival in the ANA and TAM groups.
- At 62 months, the benefits of ZOL were decreased bone metastases, decreased contralateral breast cancer, decreased locoregional and distant metastases and improved disease-free survival.
- ZOL did not increase the incidence of serious adverse events compared with endocrine therapy alone.
- ESMO 2010 guidelines now recommend that ZOL may be appropriate for premenopausal women receiving aromatase inhibitor therapy (Ann Oncol 2010;21[suppl 5]:v9-14).

Ongoing Adjuvant Bisphosphonate Trials in Breast Cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Target Accrual</th>
<th>Arms</th>
<th>Study Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>SWOG-S0307</td>
<td>III</td>
<td>5,400 (closed)</td>
<td>Zoledronic acid Clodronate Ibandronate</td>
<td>Disease recurrence Disease-free survival Overall survival</td>
</tr>
<tr>
<td>NSABP-B-34</td>
<td>III</td>
<td>3,323 (closed)</td>
<td>Clodronate Placebo</td>
<td>Disease-free survival Skeletal metastasis Overall survival</td>
</tr>
<tr>
<td>NCT00196872 (German Breast Group)</td>
<td>III</td>
<td>3,000 (open)</td>
<td>Ibandronate Observation</td>
<td>Disease-free survival Overall survival</td>
</tr>
<tr>
<td>NCT00196859 (ICE)</td>
<td>III</td>
<td>1,500 (open)</td>
<td>Ibandronate Ibandronate + capecitabine</td>
<td>Local/distant relapse Deaths Bone fracture/surgery</td>
</tr>
</tbody>
</table>


Investigator Commentary: Carry-Over Effect of Adjuvant Zoledronic Acid in ABCSG-12

ABCSG-12 was an adjuvant study in younger women who received ovarian suppression with either tamoxifen or an aromatase inhibitor with a second randomization to zoledronic acid or not, which attempted to define the benefits of bisphosphonates in the adjuvant setting.

The study previously reported that adjuvant zoledronic acid prevented loss of bone mineral density, and a provocative finding indicated that patients who received zoledronic acid had an improvement in disease-free survival. In this report, the investigators updated their data and no major difference was evident in the safety or event profile compared to previous reports. They continued to show that zoledronic acid was associated with preservation of bone density and a small improvement in the rate of breast cancer-related events.

Since the larger and more compelling AZURE trial was completely negative, I believe most clinicians will be looking to that study to guide their treatment recommendations.

Interview with Harold J Burstein, MD, PhD, December 22, 2010.